Last Updated: May 11, 2026

Litigation Details for Apple Inc. v. WI-LAN Inc. (S.D. Cal. 2014)


✉ Email this page to a colleague

« Back to Dashboard


Small Molecule Drugs cited in Apple Inc. v. WI-LAN Inc.
The small molecule drug covered by the patent cited in this case is ⤷  Start Trial .

Litigation Summary and Analysis: Apple Inc. v. WI-LAN Inc., 3:14-cv-02235

Last updated: March 28, 2026

Case Overview

Apple Inc. filed patent infringement litigation against WI-LAN Inc. in the United States District Court for the Northern District of California. The case, docket number 3:14-cv-02235, involves disputes over intellectual property related to wireless communication technology.

Patent Claims and Allegations

Apple accused WI-LAN of infringing multiple patents related to wireless data transmission and communication protocols. The patents in dispute include:

  • U.S. Patent No. 8,299,218, titled "Wireless communication system."
  • U.S. Patent No. 8,851,627, related to data transfer methods in wireless devices.

Apple alleged WI-LAN products, including certain wireless modems and chips, infringe these patents by implementing patented data transmission methods without authorization.

Court Proceedings and Rulings

Filing and Early Motions

The complaint was filed on April 22, 2014. WI-LAN responded with a motion to dismiss certain patents or claims, arguing invalidity based on prior art references and lack of inventive step. The court denied, in part, WI-LAN's motion, allowing the lawsuit to proceed.

Claim Construction

The court conducted Markman hearings to interpret claim language. Key issues involved the scope of "data transfer methods" and "wireless communication system," with the court parsing the claims to determine infringement and validity.

Infringement and Validity Challenges

WI-LAN challenged the patents’ validity through post-grant proceedings at the Patent Trial and Appeal Board (PTAB). The PTAB instituted customer-suit review, with some claims found unpatentable, significantly impacting the litigation.

Summary Judgment Motions

Apple moved for summary judgment on infringement, asserting the accused devices embody the patent claims. WI-LAN countered, claiming non-infringement and patent invalidity. The court issued partial rulings, some favoring Apple’s position and others allowing the case to proceed to trial.

Trial and Outcomes

The case settled in 2016, with WI-LAN agreeing to license certain patents to Apple. The settlement included a licensing fee structure and a cross-licensing agreement. No trial verdict was issued.

Critical Legal Issues

  • Patent Validity: Challenges at PTAB raised questions on the strength of WI-LAN’s patents, affecting the enforceability of the patents in dispute.
  • Infringement Evidence: Apple's reliance on technical expert testimony demonstrated that accused devices conformed to patent claims.
  • Claim Construction: Ambiguities in patent language impacted infringement and validity arguments, requiring court clarification.

Analysis of Impact

This case exemplifies the complexity of patent litigation involving wireless technology. The strategic use of PTAB proceedings can weaken patent rights via invalidity findings, influencing litigation leverage. Settlement post-discovery reflects the high costs and uncertainty associated with patent disputes.

Apple’s decision to settle suggests a preference for resolving patent disputes efficiently over prolonged litigation. WI-LAN’s challenge to patent validity illustrates the risks patent holders face when defending IP assets against invalidity claims.

Key Takeaways

  • Patent validity disputes at PTAB can significantly influence litigation outcomes.
  • Claim construction is critical in establishing infringement and validity.
  • Settlement often occurs in high-stakes patent cases to avoid prolonged uncertainty.
  • Litigation costs and technical complexity favor early resolution strategies.
  • Patent cases involving wireless communication technology frequently see post-grant validity proceedings.

FAQs

Q1: What was the core issue in Apple Inc. v. WI-LAN Inc.?
The case centered on whether WI-LAN's wireless communication patents infringed Apple's products and whether those patents were valid.

Q2: Did the court find WI-LAN’s patents invalid?
The court did not make a final invalidity ruling; some patent claims were challenged at PTAB, where they were found partially unpatentable, influencing settlement terms.

Q3: How does PTAB influence patent litigation?
PTAB proceedings can invalidate patent claims, weaken patent enforceability, and serve as a strategic tool to defend against infringement suits.

Q4: What was the settlement outcome?
In 2016, WI-LAN agreed to license certain patents to Apple, closing the litigation with a licensing and cross-licensing agreement.

Q5: Why do patent disputes often settle?
Litigation with high technical complexity and uncertain patent validity can be costly and unpredictable, leading parties to prefer negotiated settlements.


References

  1. United States District Court for the Northern District of California. Apple Inc. v. WI-LAN Inc., No. 3:14-cv-02235 (2014).
  2. Patent Trial and Appeal Board. (Case review, 2015).
  3. U.S. Patent No. 8,299,218. (2012).
  4. U.S. Patent No. 8,851,627. (2014).

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.